MX347324B - Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad. - Google Patents

Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.

Info

Publication number
MX347324B
MX347324B MX2013010342A MX2013010342A MX347324B MX 347324 B MX347324 B MX 347324B MX 2013010342 A MX2013010342 A MX 2013010342A MX 2013010342 A MX2013010342 A MX 2013010342A MX 347324 B MX347324 B MX 347324B
Authority
MX
Mexico
Prior art keywords
low dose
treating autoimmune
inflammatory disorders
autoimmune
relates
Prior art date
Application number
MX2013010342A
Other languages
English (en)
Other versions
MX2013010342A (es
Inventor
Klatzmann David
Saadoun David
Cacoub Patrice
Rosenzwajg Michèle
Bensimon Gilbert
Bernard Claude
Piaggio Eliane
Original Assignee
Assist Publique-Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44244599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347324(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assist Publique-Hôpitaux De Paris filed Critical Assist Publique-Hôpitaux De Paris
Publication of MX2013010342A publication Critical patent/MX2013010342A/es
Publication of MX347324B publication Critical patent/MX347324B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere tratamientos novedosos basados en IL-2 para tratar enfermedades autoinmunes e inflamatorias. De forma más específica, la presente invención se refiere al uso de una dosis baja de IL-2 para el tratamiento de la diabetes de tipo I y otras enfermedades autoinmunes y/o inflamatorias.
MX2013010342A 2011-03-11 2012-03-09 Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad. MX347324B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451663P 2011-03-11 2011-03-11
EP11305269 2011-03-11
PCT/EP2012/054174 WO2012123381A1 (en) 2011-03-11 2012-03-09 Use of low dose il-2 for treating autoimmune - related or inflammatory disorders

Publications (2)

Publication Number Publication Date
MX2013010342A MX2013010342A (es) 2014-03-05
MX347324B true MX347324B (es) 2017-04-19

Family

ID=44244599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010342A MX347324B (es) 2011-03-11 2012-03-09 Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.

Country Status (12)

Country Link
US (1) US20230149512A1 (es)
EP (3) EP3443979B1 (es)
JP (2) JP6054889B2 (es)
KR (1) KR102220006B1 (es)
CN (2) CN109432407A (es)
AU (4) AU2012228418B2 (es)
CA (1) CA2828657A1 (es)
DK (2) DK3443979T3 (es)
ES (1) ES2693645T3 (es)
MX (1) MX347324B (es)
PL (2) PL2683395T3 (es)
WO (1) WO2012123381A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
KR20210041631A (ko) * 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
US10183061B2 (en) 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
BR112016018288A2 (pt) 2014-02-06 2017-10-10 Hoffmann La Roche proteínas de fusão de interleucina 2 e uso das mesmas
EP2918285A1 (en) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
CN104189892A (zh) * 2014-08-22 2014-12-10 北京大学人民医院 低剂量白细胞介素2在免疫相关性疾病治疗中的应用
CA2963602A1 (en) * 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
CN104459129A (zh) * 2015-01-05 2015-03-25 复旦大学附属华山医院 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
TN2017000432A1 (en) 2015-04-10 2019-04-12 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
EP3313429B1 (en) * 2015-06-19 2021-10-06 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection
CA2997946A1 (en) * 2015-09-10 2017-03-16 Assistance Publique - Hopitaux De Paris Use of interleukin 2 for treating spondyloarthritis
US11191743B2 (en) * 2016-01-11 2021-12-07 Dignity Health Modulators of zinc activated cation channel
JP6911044B2 (ja) * 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US11618884B2 (en) * 2017-11-14 2023-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019158764A1 (en) * 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
JP7235772B2 (ja) * 2018-05-21 2023-03-08 ネクター セラピューティクス 選択的Ｔｒｅｇ刺激因子ＲＵＲ２０ｋＤ－ＩＬ－２及び関連組成物
WO2020007937A1 (en) * 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US20200282013A1 (en) * 2019-03-08 2020-09-10 DrugCendR, Inc. Low-dose cytokine co-administered with irgd for treating cancer
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
CN110251659A (zh) * 2019-07-03 2019-09-20 安徽省立医院 一种小剂量白细胞介素2在制备治疗慢性痛风药物中的应用
TW202118774A (zh) 2019-07-26 2021-05-16 美商威特拉公司 介白素-2藥劑及其用途
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
TW202146041A (zh) 2020-03-06 2021-12-16 尼姆大學醫學中心 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
CN113304248B (zh) * 2021-07-01 2023-01-03 北京大学人民医院 Il-2在制备缓解糖皮质激素类药物副作用的药物中的应用
CN115607653B (zh) * 2022-07-09 2023-09-26 曹霞 低剂量白介素2在治疗孤独症中的应用
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
CN115779072B (zh) * 2023-02-06 2023-10-17 北京大学第三医院（北京大学第三临床医学院） 一种包含低浓度il-2的用于治疗干眼的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
EP0262802A3 (en) 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
JPS63183538A (ja) * 1986-09-01 1988-07-28 Takeda Chem Ind Ltd 関節リウマチまたは全身性エリテマト−デスの改善，治療剤
US5466447A (en) * 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
AU7578091A (en) 1990-03-19 1991-10-21 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
GB9724838D0 (en) 1997-11-26 1998-01-21 Franks Christopher R Compositions
WO2002078624A2 (en) * 2001-03-30 2002-10-10 Mayo Foundation For Medical Education And Research Aerosol administration of interleukin-2 liposomes
WO2003075670A1 (en) * 2002-03-08 2003-09-18 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
ATE441420T1 (de) * 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
EP1846020B1 (en) 2005-01-27 2013-08-21 Novartis Vaccines and Diagnostics, Inc. Methods for treating renal cell carcinoma
JP5604311B2 (ja) 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物

Also Published As

Publication number Publication date
CN109432407A (zh) 2019-03-08
PL2683395T3 (pl) 2019-04-30
EP2683395B1 (en) 2018-08-01
JP6054889B2 (ja) 2016-12-27
DK3443979T3 (da) 2020-08-24
MX2013010342A (es) 2014-03-05
EP3443979A1 (en) 2019-02-20
AU2016273847B2 (en) 2018-04-19
ES2693645T3 (es) 2018-12-13
AU2018206705A1 (en) 2018-08-02
JP2023029565A (ja) 2023-03-03
DK2683395T3 (en) 2018-11-19
AU2018206705B2 (en) 2020-03-19
KR102220006B1 (ko) 2021-02-24
AU2016273847A1 (en) 2017-01-05
WO2012123381A1 (en) 2012-09-20
US20230149512A1 (en) 2023-05-18
EP3766513A1 (en) 2021-01-20
JP7561893B2 (ja) 2024-10-04
AU2020204023B2 (en) 2022-06-02
AU2020204023A1 (en) 2020-07-09
PL3443979T3 (pl) 2020-11-16
EP3443979B1 (en) 2020-05-27
CN103732241A (zh) 2014-04-16
EP2683395A1 (en) 2014-01-15
AU2016273847A2 (en) 2017-02-02
AU2012228418A1 (en) 2013-09-05
JP2014510725A (ja) 2014-05-01
AU2012228418B2 (en) 2016-09-29
KR20140053869A (ko) 2014-05-08
CA2828657A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
MX2013010342A (es) Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad.
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
MX2015008114A (es) Derivados de exendina-4.
MY170713A (en) Treatment protocol of diabetes type 2
MX2014015423A (es) Analogos de peptido de exedina-4.
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
MX2015015249A (es) Peptidos terapeuticos.
AU2011328009A8 (en) Compounds and methods for treating pain
EA201590359A1 (ru) Лечение ревматоидного артрита
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
NZ610891A (en) Cd89 activation in therapy
SG179203A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016004325A (es) Nuevo derivado de un analogo de insulina.
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12015500322B1 (en) Tris(hetero)arylpyrazoles and use thereof

Legal Events

Date Code Title Description
FG Grant or registration